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lated for paired observations between IBDQ and EQ-5D (n =
3320) and IBDQ and SF-6D (n = 3230). Least square regression
models were investigated. RESULTS: The decile analysis demon-
strated a consistent positive relationship with both utility scores.
The correlations between the IBDQ and both the EQ-5D and SF-
6D were statistically highly signiﬁcant (p < 0.0001). The corre-
lation coefﬁcients for IBDQ with SF-6D and with EQ-5D were
0.85 and 0.76 respectively. A simple linear least square regres-
sion model of the relationship between EQ-5D and IBDQ
explained 46% of the variance. A visual inspection of the 
residuals plot for the IBDQ/SF-6D model suggested some non-
linearity and an improved non-linear model explained 72% of
the variance. The comparison of the two sets of values demon-
strated the commonly observed ceiling effect for the EQ-5D 
and ﬂoor effect for the SF-6D and provided added face validity
for the transformations. CONCLUSIONS: Given the strength,
consistency, and predictable characteristics of the relationships,
the algorithms appear to provide valuable and valid methods 
to estimate utilities from IBDQ scores in trials of Crohn’s 
disease patients that have collected IBDQ scores but not utilities.
The generalisability of this relationship to other groups of
patients, for which the IBDQ is appropriate, should be 
investigated.
UB2
QUANTIFYING THE RELATIONSHIP BETWEEN DISEASE
SEVERITY, UTILITY AND HEALTH CARE RESOURCE USE IN
CROHN’S DISEASE
Weston AR1, Gibson PR2, Florin T3, Macrae F4, Radford-Smith G5,
Shann A6, Lawrance I7
1Health Technology Analysts Pty Ltd, Sydney, NSW, Australia; 2Box Hill
Hospital, Box Hill,VIC, Australia; 3Mater Health Services Adult
Hospital, Brisbane, QLD, Australia; 4The Royal Melbourne Hospital,
Melbourne,VIC, Australia; 5Royal Brisbane Hospital, Brisbane, QLD,
Australia; 6Schering-Plough, Sydney, NSW, Australia; 7Fremantle
Hospital, Fremantle, WA, Australia
OBJECTIVES: To assess the relationship between (i) disease
severity and quality of life and (ii) disease severity and health
care resource use, in patients with Crohn’s disease. METHODS:
A prospective, cross sectional, pharmacoeconomics study was
conducted in ﬁve centres in Australia, with patients recruited by
specialist gastroenterologists. Each patient completed question-
naires comprising demographic, disease and health care utilisa-
tion questions, together with the disease-speciﬁc Inﬂammatory
Bowel Disease Questionnaire (IBDQ) and the Assessment of
Quality of Life (AQoL) multi-attribute utility instrument.
Disease severity was assessed by the gastroenterologist, using the
Crohn’s Disease Activity Index (CDAI). RESULTS: Of the 154
patients recruited, 11 were excluded due to incomplete datasets
or signiﬁcant co-morbidity. The 143 patients analysed had a
broad range of disease severity (CDAI 36-446), and included
23% with enterocutaneous ﬁstulae. Stepwise regression analyses
showed a negative relationship between disease severity and
quality of life—irrespective of whether the latter was measured
by the IBDQ (p < 0.0001) or the AQoL utility instrument (p <
0.0001). Age, gender and years since diagnosis did not signiﬁ-
cantly impact upon either of the quality of life outcomes. Health
care resource utilisation increased with increasing CDAI (p <
0.001), with hospital admissions being the largest component
cost. Even when patients with ﬁstulae were excluded, the mean
treatment cost for the most severe group (CDAI >= 220) was
AUD$7852 annually, excluding medications. Finally, despite
their young age (mean = 38yrs), 27% of patients received a Gov-
ernment beneﬁt; with the majority of these stating that this was
primarily due to their Crohn’s disease. CONCLUSIONS: More
severe Crohn’s disease is associated with poor quality of life for
patients and places considerable burden upon health care and
social welfare resources.
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OBJECTIVES: To compare 2 preference-based measures of
health, the EQ-5D and the SF-6D, in patients with pulmonary
arterial hypertension (PAH). METHODS: PAH patients (n =
278) were administered the EQ-5D and SF-36 questionnaires in
a sildenaﬁl clinical study. Comparisons of the utility indices of
the EQ-5D and the SF-36 (the SF-6D) were conducted using the
study baseline data. Comparisons were made using the total
group of patients, and a sub-group analysis by functional class
was also conducted. Functional class was assessed using the
WHO criteria for functional capacity and therapeutic class in
patients with PAH; there are 4 WHO functional classes (FC
I–IV), with higher classes associated with greater limitations in
physical activity. RESULTS: In the total group of patients, the
mean (SD) utility index scores of the EQ-5D and the SF-36 were
similar (0.632 [0.254] vs. 0.627 [0.116]), and the single-measure
intra-class correlation coefﬁcient between them was 0.51. Base-
line FC for treated patients was distributed as follows: FC I,
0.4%; FC II, 38.6%; FC III, 57.6%; FC IV, 3.2%. Given the low
proportions of subjects in FC I and FC IV, analyses were per-
formed on the combined groups of FC I/II and FC III/IV. The
mean (SD) utility index score of the EQ-5D exceeded the SF-6D
score in FC I/II patients (0.720 [0.205] vs. 0.672 [0.122]), but
was lower than the SF-6D score in FC III/IV patients (0.574
[0.266] vs. 0.597 [0.102]). CONCLUSIONS: The EQ-5D and
the SF-36 utility indices provide similar estimates for PAH
patients overall. However, the agreement between the instru-
ments is not consistent over the range of functional classes seen
in PAH patients.
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OBJECTIVES: Currently, there is only limited research into the
main determinants of QoL in patients with psoriatic arthritis
(PsA). With a number of novel treatments for PsA emerging, we
examined the associations between clinical outcomes and health
utilities for the purposes of economic evaluation. METHODS:
Patient-level data from a pivotal, Phase III, randomized con-
trolled trial of the fully human, anti-tumor necrosis factor mon-
oclonal antibody, adalimumab, vs. placebo in the treatment 
of PsA were analyzed. All potentially relevant outcomes were
included: patient-reported functional loss measured by the
Health Assessment Questionnaire Disability Index (HAQ-DI),
physician’s assessment of psoriasis severity from the Psoriasis
Area Severity Index (PASI), tender and swollen joint counts (TJC,
SJC), age, sex, and disease duration. All measurements were col-
lected for patients at baseline and Weeks 12 and 24. The health
utility measurement, the SF-6D was derived from responses to
the Short Form-36, a generic QoL questionnaire. Multiple linear
regressions using generalized estimating equations were
employed to identify signiﬁcant predictors of the SF-6D.
RESULTS: Mean baseline characteristics for 313 patients
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included age = 49 years, disease duration = 9.5 years, TJC = 24,
SJC = 14, HAQ-DI = 1.0, and PASI = 7.9. Forty-four percent of
patients were female. Pearson correlation coefﬁcients between
variables were -0.6 (HAQ-DI and SF-6D, p < 0.05), -0.2 (PASI
and SF-6D, p < 0.05) and 0.1 (HAQ-DI and PASI, p = 0.2) As
determined by multiple linear regression, signiﬁcant independent
predictors of PsA-related QoL (in descending order of impor-
tance) were: functional loss (HAQ-DI), severity of psoriasis
(PASI), and TJC (all p < 0.05). SJC was not a signiﬁcant predic-
tor of QoL in PsA. CONCLUSIONS: In patients with PsA, the
main determinants of QoL measured were degree of disease-
related functional loss and severity of skin disease. In contrast to
ﬁndings in rheumatoid arthritis, joint counts were of secondary
importance. These ﬁndings have important implications for eco-
nomic evaluations of new treatments for PsA.
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OBJECTIVE: the management of hemophilic patients is very
expensive. This situation becomes extreme when patients
develop inhibitors, which comprises the effectiveness of treat-
ment, with potential increase of morbidity and mortality. We
compared cost of care and Health-Related Quality-of-Life
(HRQoL) between hemophilic patients with (INHIB+) and those
without (INHIB-) inhibitors. METHODS: INHIB+ was enrolled
in the Cost Of Care Inhibitors Study (COCIS) [Gringeri et al,
Blood 2003]; INHIB- was enrolled in the Cost Of Care of
HEmophilia (COCHE) study: naturalistic, multicentre, longitu-
dinal studies involving patients enrolled at the Italian Hemo-
philia Centres. Results are reported on: cost with clotting factor
concentrates evaluated from the Italian National Health Service’s
point of view, HRQoL evaluated with the EuroQol and Short
Form-36. The bootstrap resampling method (5000 samples) was
applied as a statistical approach to compare the two groups.
RESULTS: INHIB+ was 52: median age 35 years (15–64), 100%
with hemophilia A, 94.2% with severe hemophilia, 98% high
responders. INHIB- was 232: median age 34.3 years (18–74),
86.6% with hemophilia A, 72.4% with severe hemophilia.
Patients with inhibitors bled signiﬁcantly less frequently than
patients without inhibitors (p < 0.0001): INHIB+ reported on
average 0.59 hemorrhages/patient/month to joints and muscles
(median = 0.33, 0–2.61), INHIB- had 2.10 hemorrhages/
patient/month (median = 1.44, 0–26.0). On average 0.16 chirur-
gical interventions/patient/year were performed to INHIB+
(19.2% patients involved), 0.35 interventions/patient/year were
performed to INHIB- (16.4% patients involved). Overall, cost
of care for INHIB+ was 17.725 €/patient/month; cost for
INHIB- was 8.341 €/patient/month, 16.473 €/patient/month to
treat patients on prophylaxis and 4.2 to treat those on demand
regimen. in the two groups HRQoL was similar, concerning both
the physical and mental components. CONCLUSION: treatment
for INHIB+ patients is much more costly than that for INHIB-
patients, is effective and allows reaching good levels of HRQoL,
similar to those perceived by INHIB- patients.
UH2
COST DRIVERS IN MULTIPLE MYELOMA TREATMENT—A 2
YEAR ANALYSIS FROM A MULTICOUNTRY RETROPROJECTED
CHART REVIEW
Moeremans K1, Caekelbergh K1, Spaepen E1,Annemans L1,
Dhawan R2
1IMS Health, Brussels, Belgium; 2Johnson & Johnson Pharmaceutical
Services LLC, Raritan, NJ, USA
OBJECTIVES: Information on costs of multiple myeloma (MM)
management is scarce. The objective of this incidence–based
cost–of–illness study was to assess direct medical costs and cost
drivers in major disease phases: primary diagnosis (PD), recur-
rent (RCD) or refractory disease (RFD). METHODS: A retro
projected chart review was performed in 9 centres (n = 176, ran-
domly selected patients) in Belgium (n = 56), France (n = 41),
UK (n = 40) and Germany (n = 39). Costs were calculated from
the payer’s perspective by multiplying resource utilization with
local unit costs from ofﬁcial sources. Data collection covered the
2–year period (or up to death) following treatment initiation in
2001. Descriptive statistics were performed on costs. Cost
drivers were identiﬁed using a linear mixed regression model.
RESULTS: The sample included 49% PD, 41% RCD and 10%
RFD. Stem–cell or bone marrow transplantation rate was 52%.
For PD, RCD and RFD respectively, 2–year costs were €59,648,
€47,039 and €46,362, of which approximately 80% incurred
during the ﬁrst year. Transplantation rates differed between
countries (39%–73%) and disease phase (68%, 40% and 28%
in PD, RCD and RFD). Descriptive cost analysis showed poten-
tial impact of phase, survival, transplantation and centre. The
regression model suggested costs to increase with number of
transplantations (p < 0.0001), increasing stage at diagnosis (p =
0.0097), occurrence of complications (p = 0.0194) and decreas-
ing age (p = 0.0004). The mean total cost was €31,612
(€26,300–€34,300) in patients without transplantation com-
pared to €59,915 (€53,000–€66,600) in the transplant popula-
tion. CONCLUSION: The study provided insight into cost
drivers in MM. The main therapeutic cost driver was transplan-
tation. Important centre–speciﬁc variation exists in transplanta-
tion accessibility. In addition, there is a lack of consensus on
transplantation practices. Since the current study was undersized
to represent national transplantation rates, further research is
needed to establish real life transplantation rates in different MM
settings.
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OBJECTIVE: To estimate the current and future economic
burden of Overactive Bladder (OAB) in males in ﬁve European
countries. METHOD: A cost of illness model estimated the
annual cost of managing OAB in Germany, Italy, Spain, Sweden
and the UK by deﬁning a locally relevant package of care and
multiplying resources used by country-speciﬁc unit cost data.
The total cost of OAB in males was calculated by multiplying
the estimated prevalence of OAB in males by the estimated
annual direct cost of OAB management. The model also esti-
mated the likely economic impact of increasing numbers of
elderly men. RESULTS: The prevalence of OAB is known to be
highest in the elderly and is commonly perceived to affect mostly
women. However, in this study, 9.6m males aged >40 were esti-
